Strategies to induce broadly protective antibody responses to viral glycoproteins

Expert Review of Vaccines

Volumn 16, Issue 5, 2017, Pages 503-513

  Krammer, F ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

arenavirus; conserved epitope; filovirus; HCV; hemagglutinin; heterosubtypic immunity; HIV; Influenza; universal vaccine; viral glycoproteins

Indexed keywords

ANTIGEN; GLYCAN; GLYCAN DERIVATIVE; GLYCOPROTEIN; INFLUENZA VACCINE; VIRAL PROTEIN; VIRUS ANTIGEN; VIRUS VACCINE;

ANTIBODY RESPONSE; HUMAN; INFLUENZA VIRUS; PRIORITY JOURNAL; REVIEW; VACCINATION; ANIMAL; ANTIBODY PRODUCTION; DISEASE MODEL; DRUG DEVELOPMENT; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MEDICAL RESEARCH; TRENDS; VIRUS DISEASES;

ANIMALS; ANTIBODY FORMATION; ANTIGENS, VIRAL; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; GLYCOPROTEINS; HUMANS; IMMUNIZATION SCHEDULE; VIRAL PROTEINS; VIRAL VACCINES; VIRUS DISEASES;

EID: 85017536430     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1080/14760584.2017.1299576     Document Type: Review

References (136)

1. Krammer F, Palese P., Advances in the development of influenza virus vaccines. Nat Rev Drug Discov. 2015;14(3):167–182.
2. Tong S, Zhu X, Li Y, et al. New world bats harbor diverse influenza A viruses. Plos Pathog. 2013;9(10):e1003657.
3. Tong S, Li Y, Rivailler P, et al. A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A. 2012;109(11):4269–4274.
4. Runstadler J, Hill N, Hussein IT, et al. Connecting the study of wild influenza with the potential for pandemic disease. Infect Genet Evol. 2013;17:162–187.
5. Van De Sandt CE, Bodewes R, Rimmelzwaan GF, et al. Influenza B viruses:not to be discounted. Future Microbiol. 2015;10(9):1447–1465.
6. Krammer F., Emerging influenza viruses and the prospect of a universal influenza virus vaccine. Biotechnol J. 2015;10(5):690–701.
7. Gerdil C. The annual production cycle for influenza vaccine. Vaccine. 2003;21(16):1776–1779.
8. De Jong JC, Beyer WE, Palache AM, et al. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol. 2000;61(1):94–99.
9. Xie H, Wan XF, Ye Z, et al. H3N2 mismatch of 2014-15 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps. Sci Rep. 2015;5:15279.
10. Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008;453(7195):667–671.
11. Throsby M, Van Den Brink E, Jongeneelen M, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. Plos ONE. 2008;3(12):e3942.
12. Wilson PC, Andrews SF. Tools to therapeutically harness the human antibody response. Nat Rev Immunol. 2012;12(10):709–719.
13. Corti D, Suguitan AL, Pinna D, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest. 2010;120(5):1663–1673.
14. Ferrari G, Haynes BF, Koenig S, et al. Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. Nat Rev Drug Discov. 2016;15(12):823–834.
15. West AP, Scharf L, Scheid JF, et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell. 2014;156(4):633–648.
16. Merk A, Subramaniam S. HIV-1 envelope glycoprotein structure. Curr Opin Struct Biol. 2013;23(2):268–276.
17. Wrammert J, Koutsonanos D, Li GM, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011;208(1):181–193.
18. Henry Dunand CJ, Leon PE, Kaur K, et al. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest. 2015;125(3):1255–1268.
19. Henry Dunand CJ, Leon PE, Huang M, et al. Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection. Cell Host Microbe. 2016;19(6):800–813.• Reports broadly reactive, nonneutralizing but protective human cross-reactive antibodies.
20. Ekiert DC, Wilson IA. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr Opin Virol. 2012;2(2):134–141.
21. Ekiert DC, Bhabha G, Elsliger MA, et al. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009;324(5924):246–251.
22. Sui J, Hwang WC, Perez S, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009;16(3):265–273.
23. Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333(6044):850–856.
24. Moody MA, Zhang R, Walter EB, et al. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. Plos One. 2011;6(10):e25797.
25. Whittle JR, Zhang R, Khurana S, et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A. 2011;108(34):14216–14221.
26. Krause JC, Tsibane T, Tumpey TM, et al. Human Monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses. J Virol. 2012;86(11):6334–6340.
27. Krause JC, Tsibane T, Tumpey TM, et al. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol. 2011;85(20):10905–10908.
28. Saphire EO. An update on the use of antibodies against the filoviruses. Immunotherapy. 2013;5(11):1221–1233.
29. Flyak AI, Shen X, Murin CD, et al. Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection. Cell. 2016;164(3):392–405.
30. Murin CD, Fusco ML, Bornholdt ZA, et al. Structures of protective antibodies reveal sites of vulnerability on ebola virus. Proc Natl Acad Sci U S A. 2014;111(48):17182–17187.
31. McElroy AK, Akondy RS, Davis CW, et al. Human ebola virus infection results in substantial immune activation. Proc Natl Acad Sci U S A. 2015;112(15):4719–4724.
32. Hashiguchi T, Fusco ML, Bornholdt ZA, et al. Structural basis for marburg virus neutralization by a cross-reactive human antibody. Cell. 2015;160(5):904–912.
33. Flyak AI, Ilinykh PA, Murin CD, et al. Mechanism of human antibody-mediated neutralization of marburg virus. Cell. 2015;160(5):893–903.
34. Corti D, Bianchi S, Vanzetta F, et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature. 2013;501(7467):439–443.
35. Robinson JE, Hastie KM, Cross RW, et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both lassa virus glycoprotein subunits. Nat Commun. 2016;7:11544.
36. Tan GS, Leon PE, Albrecht RA, et al. Broadly-reactive neutralizing and non-neutralizing antibodies directed against the h7 influenza virus hemagglutinin reveal divergent mechanisms of protection. Plos Pathog. 2016;12(4):e1005578.
37. He W, Tan GS, Mullarkey CE, et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc Natl Acad Sci U S A. 2016;113(42):11931–11936.
38. Krammer F, Palese P, Steel J. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr Top Microbiol Immunol. 2015;386:301–321.
39. Andrews SF, Huang Y, Kaur K, et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med. 2015;7(316):316ra192.
40. Avnir Y, Tallarico AS, Zhu Q, et al. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. Plos Pathog. 2014;10(5):e1004103.
41. Avnir Y, Watson CT, Glanville J, et al. IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity. Sci Rep. 2016;6:20842.
42. He W, Mullarkey CE, Duty JA, et al. Broadly neutralizing anti-influenza virus antibodies:enhancement of neutralizing potency in polyclonal mixtures and IgA backbones. J Virol. 2015;89(7):3610–3618.
43. Krammer F. Novel universal influenza virus vaccine approaches. Curr Opin Virol. 2016;17:95–103.
44. Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol. 2013;3(5):521–530.
45. Dilillo DJ, Tan GS, Palese P, et al. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med. 2014;20(2):143–151.•• Reports the dependece of broadly-protective anti-HA stalk antibodies on effector functions.
46. Doud MB, Bloom JD. Accurate measurement of the effects of all amino-acid mutations on influenza hemagglutinin. Viruses. 2016;8:6.• Highly interesting mutagenesis analysis of the plasticity of the influenza virus hemagglutinin.
47. Heaton NS, Sachs D, Chen CJ, et al. Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. Proc Natl Acad Sci U S A. 2013;110(50):20248–20253.• Highly interesting mutagenesis analysis of the plasticity of all influenza virus genes.
48. Chai N, Swem LR, Reichelt M, et al. Two escape mechanisms of influenza a virus to a broadly neutralizing stalk-binding antibody. Plos Pathog. 2016;12(6):e1005702.
49. Francis T. On the doctrine of original antigenic sin. Proc Am Philos Soc. 1960;104(6):572–578.• Original paper on OAS. A must read for every influenza virus aficionado.
50. Park MS, Kim JI, Park S, et al. Sin response to RNA viruses and antiviral immunity. Immune Netw. 2016;16(5):261–270.
51. Lessler J, Riley S, Read JM, et al. Evidence for antigenic seniority in influenza A (H3N2) antibody responses in southern China. Plos Pathog. 2012;8(7):e1002802.
52. Nachbagauer R, Choi A, Izikson R, et al. Age dependence and isotype specificity of influenza virus hemagglutinin stalk-reactive antibodies in humans. MBio. 2016;7:1.
53. Li Y, Myers JL, Bostick DL, et al. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J Exp Med. 2013;210(8):1493–1500.
54. Linderman SL, Hensley SE. Antibodies with ‘original antigenic sin’ properties are valuable components of secondary immune responses to influenza viruses. Plos Pathog. 2016;12(8):e1005806.• Very detailed analysis of antigenic sin and recall responses against influenza viruses in mice on a monoclonal level.
55. Pica N, Hai R, Krammer F, et al. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A. 2012;109(7):2573–2578.
56. Thomson CA, Wang Y, Jackson LM, et al. Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem. Front Immunol. 2012;3:87.
57. Krammer F, Pica N, Hai R, et al. Hemagglutinin stalk-reactive antibodies are boosted following sequential infection with seasonal and pandemic h1n1 influenza virus in mice. J Virol. 2012;86(19):10302–10307.
58. Kirchenbaum GA, Carter DM, Ross TM. Sequential infection in ferrets with antigenically distinct seasonal h1n1 influenza viruses boosts hemagglutinin stalk-specific antibodies. J Virol. 2015;90(2):1116–1128.
59. Ellebedy AH, Krammer F, Li GM, et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc Natl Acad Sci U S A. 2014;111(36):13133–13138.
60. Nachbagauer R, Wohlbold TJ, Hirsh A, et al. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol. 2014;88(22):13260–13268.
61. Halliley JL, Khurana S, Krammer F, et al. High-affinity H7 head and stalk domain-specific antibody responses to an inactivated influenza h7n7 vaccine after priming with live attenuated influenza vaccine. J Infect Dis. 2015;212(8):1270–1278.
62. Krammer F, Jul-Larsen A, Margine I, et al. An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clin Vaccine Immunol. 2014;21(8):1153–1163.
63. Palese P, Wang TT. Why do influenza virus subtypes die out? A hypothesis. MBio. 2011;2:5.
64. Tan GS, Krammer F, Eggink D, et al. A pan-h1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol. 2012;86(11):6179–6188.
65. Tan GS, Lee PS, Hoffman RM, et al. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014;88(23):13580–13592. doi:10.1128/JVI.02289-14.
66. Wang TT, Tan GS, Hai R, et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. Plos Pathog. 2010;6(2):e1000796.
67. Hai R, Krammer F, Tan GS, et al. Influenza viruses expressing chimeric hemagglutinins:globular head and stalk domains derived from different subtypes. J Virol. 2012;86(10):5774–5781.
68. Chen CJ, Ermler ME, Tan GS, et al. A viruses expressing intra- or intergroup chimeric hemagglutinins. J Virol. 2016;90(7):3789–3793.
69. Ryder AB, Nachbagauer R, Buonocore L, et al. Vaccination with vesicular stomatitis virus-vectored chimeric hemagglutinins protects mice against divergent influenza virus challenge strains. J Virol. 2015;90(5):2544–2550.
70. Margine I, Krammer F, Hai R, et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza a viruses. J Virol. 2013;87(19):10435–10446.
71. Nachbagauer R, Miller MS, Hai R, et al. Hemagglutinin stalk immunity reduces influenza virus replication and transmission in ferrets. J Virol. 2015;90(6):3268–3273.
72. Krammer F, Margine I, Hai R, et al. H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol. 2014;88(4):2340–2343.
73. Krammer F, Pica N, Hai R, et al. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol. 2013;87(12):6542–6550.
74. Krammer F, Hai R, Yondola M, et al. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol. 2014;88(6):3432–3442.
75. Nachbagauer R, Kinzler D, Choi A, et al. A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice. npj Vaccines. 2016;1:16015. doi:10.1038/npjvaccines.2016.15.
76. Fehr T, Bachmann MF, Bluethmann H, et al. T-independent activation of B cells by vesicular stomatitis virus:no evidence for the need of a second signal. Cell Immunol. 1996;168(2):184–192.
77. Bachmann MF, Hengartner H, Zinkernagel RM. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus:role of antigen patterns in B cell induction? Eur J Immunol. 1995;25(12):3445–3451.
78. Pushko P, Tretyakova I, Hidajat R, et al. Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens. Virology. 2016;501:176–182.
79. Tretyakova I, Pearce MB, Florese R, et al. Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses. Virology. 2013;442(1):67–73.
80. Pushko P, Pearce MB, Ahmad A, et al. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine. 2011;29(35):5911–5918.
81. Holtsberg FW, Shulenin S, Vu H, et al. Pan-ebolavirus and pan-filovirus mouse monoclonal antibodies:protection against ebola and sudan viruses. J Virol. 2015;90(1):266–278.
82. Keck ZY, Enterlein SG, Howell KA, et al. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J Virol. 2015;90(1):279–291.
83. Wang TT, Tan GS, Hai R, et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A. 2010;107(44):18979–18984.
84. Jiang Z, Gera L, Mant CT, et al. Platform technology to generate broadly cross-reactive antibodies to α-helical epitopes in hemagglutinin proteins from influenza a viruses. Biopolymers. 2016 Jan 21. doi:10.1002/bip.22808.
85. Mallajosyula VV, Citron M, Lu X, et al. In vitro and in vivo characterization of designed immunogens derived from the CD-helix of the stem of influenza hemagglutinin. Proteins. 2013;81(10):1759–1775.
86. Janulíková J, Staneková Z, Mucha V, et al. Two distinct regions of HA2 glycopolypeptide of influenza virus hemagglutinin elicit cross-protective immunity against influenza. Acta Virol. 2012;56(3):169–176.
87. Staneková Z, Adkins I, Kosová M, et al. Heterosubtypic protection against influenza A induced by adenylate cyclase toxoids delivering conserved HA2 subunit of hemagglutinin. Antiviral Res. 2013;97(1):24–35.
88. Gocník M, Fislová T, Mucha V, et al. Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection. J Gen Virol. 2008;89(Pt 4):958–967.
89. Ideno S, Sakai K, Yunoki M, et al. Immunization of rabbits with synthetic peptides derived from a highly conserved β-sheet epitope region underneath the receptor binding site of influenza A virus. Biologics. 2013;7:233–241.
90. Doyle TM, Hashem AM, Li C, et al. Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral Res. 2013;100(2):567–574.
91. Schotsaert M, De Filette M, Fiers W, et al. Universal M2 ectodomain-based influenza A vaccines:preclinical and clinical developments. Expert Rev Vaccines. 2009;8(4):499–508.
92. Neirynck S, Deroo T, Saelens X, et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med. 1999;5(10):1157–1163.
93. Schneemann A, Speir JA, Tan GS, et al. A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. J Virol. 2012;86(21):11686–11697.
94. Chen S, Zheng D, Li C, et al. Protection against multiple subtypes of influenza viruses by virus-like particle vaccines based on a hemagglutinin conserved epitope. Biomed Res Int. 2015;901817:2015.
95. Zheng D, Chen S, Qu D, et al. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses. Vaccine. 2016;34(51):6464–6471.
96. Klausberger M, Tscheliessnig R, Neff S, et al. Globular head-displayed conserved influenza H1 hemagglutinin stalk epitopes confer protection against heterologous H1N1 virus. Plos One. 2016;11(4):e0153579.
97. Knittelfelder R, Riemer AB, Jensen-Jarolim E. Mimotope vaccination–from allergy to cancer. Expert Opin Biol Ther. 2009;9(4):493–506.
98. Zhong Y, Cai J, Zhang C, et al. Mimotopes selected with neutralizing antibodies against multiple subtypes of influenza A. Virol J. 2011;8:542.
99. Krammer F. The quest for a universal flu vaccine:headless HA 2.0. Cell Host Microbe. 2015;18(4):395–397.
100. Laddy DJ, Yan J, Corbitt N, et al. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine. 2007;25(16):2984–2989.
101. Laddy DJ, Yan J, Kutzler M, et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. Plos One. 2008;3(6):e2517.
102. Chen MW, Cheng TJ, Huang Y, et al. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U S A. 2008;105(36):13538–13543.
103. Giles BM, Crevar CJ, Carter DM, et al. A computationally-optimized hemagglutinin VLP vaccine elicits broadly-reactive antibodies that protect non-human primates from h5n1 infection. J Infect Dis. 2012 May 15;205(10):1562–1570. doi:10.1093/infdis/jis232.​​​​
104. Giles BM, Ross TM. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine. 2011;29(16):3043–3054.
105. Crevar CJ, Carter DM, Lee KY, et al. Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades. Hum Vaccin Immunother. 2015;11(3):572–583.
106. Giles BM, Bissel SJ, Dealmeida DR, et al. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin Vaccine Immunol. 2012;19(2):128–139.
107. Ducatez MF, Bahl J, Griffin Y, et al. Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development. Proc Natl Acad Sci U S A. 2011;108(1):349–354.
108. Yan J, Villarreal DO, Racine T, et al. Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. Vaccine. 2014;32(24):2833–2842.
109. Wang B, Yu H, Yang FR, et al. Protective efficacy of a broadly cross-reactive swine influenza DNA vaccine encoding M2e, cytotoxic T lymphocyte epitope and consensus H3 hemagglutinin. Virol J. 2012;9:127.
110. Weaver EA, Rubrum AM, Webby RJ, et al. Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin. Plos One. 2011;6(3):e18314.
111. Webby RJ, Weaver EA. Centralized consensus hemagglutinin genes induce protective immunity against H1, H3 and H5 influenza viruses. Plos One. 2015;10(10):e0140702.
112. Carter DM, Darby CA, Lefoley BC, et al. Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses. J Virol. 2016;90(9):4720–4734.
113. Zhou H, Huang Y, Yuan S, et al. Sequential immunization with consensus influenza hemagglutinins raises cross-reactive neutralizing antibodies against various heterologous HA strains. Vaccine. 2017 Jan 5;35(2):305–312. doi:10.1016/j.vaccine.2016.11.051.
114. Kamlangdee A, Kingstad-Bakke B, Osorio JE. Mosaic H5 hemagglutinin provides broad humoral and cellular immune responses against influenza viruses. J Virol. 2016;90(15):6771–6783.
115. Kamlangdee A, Kingstad-Bakke B, Anderson TK, et al. Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene. J Virol. 2014;88(22):13300–13309.
116. Li SQ, Schulman JL, Moran T, et al. Influenza A virus transfectants with chimeric hemagglutinins containing epitopes from different subtypes. J Virol. 1992;66(1):399–404.
117. Barouch DH, Stephenson KE, Borducchi EN, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013;155(3):531–539.
118. Krohn K, Stanescu I, Blazevic V, et al. A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies. Microbes Infect. 2005;7(14):1405–1413.
119. Morrow MP, Tebas P, Yan J, et al. Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals. Mol Ther. 2015;23(3):591–601.
120. Yan J, Corbitt N, Pankhong P, et al. Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine. Vaccine. 2011;29(41):7173–7181.
121. Yan J, Yoon H, Kumar S, et al. Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther. 2007;15(2):411–421.
122. Latimer B, Toporovski R, Yan J, et al. Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Hum Vaccin Immunother. 2014;10(8):2357–2365.
123. Lennemann NJ, Rhein BA, Ndungo E, et al. Comprehensive functional analysis of N-linked glycans on Ebola virus GP1. MBio. 2014;5(1):e00862–00813.
124. Wang W, Nie J, Prochnow C, et al. A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Retrovirology. 2013;10:14.
125. Tate MD, Job ER, Deng YM, et al. Playing hide and seek:how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses. 2014;6(3):1294–1316.
126. Vigerust D, Shepherd V. Virus glycosylation:role in virulence and immune interactions. Trends Microbiol. 2007;15(5):211–218.
127. Medina RA, Stertz S, Manicassamy B, et al. Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses. Sci Transl Med. 2013;5(187):187ra170.•• Detailed analysis of the role of glycosylation of the influenza virus globular head domain on virus pathogenicity and immunogenicity.
128. Chen JR, Yu YH, Tseng YC, et al. Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections. Proc Natl Acad Sci U S A. 2014;111(7):2476–2481.
129. Wang CC, Chen JR, Tseng YC, et al. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci U S A. 2009;106(43):18137–18142.
130. Magadán JG, Altman MO, Ince WL, et al. Biogenesis of influenza a virus hemagglutinin cross-protective stem epitopes. Plos Pathog. 2014;10(6):e1004204.
131. Liu WC, Jan JT, Huang YJ, et al. Unmasking stem-specific neutralizing epitopes by abolishing n-linked glycosylation sites of influenza virus hemagglutinin proteins for vaccine design. J Virol. 2016;90(19):8496–8508.
132. Eggink D, Goff PH, Palese P. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. J Virol. 2014;88(1):699–704.
133. Lin SC, Liu WC, Jan JT, et al. Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. Plos One. 2014;9(3):e92822.
134. Lin SC, Lin YF, Chong P, et al. Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles. Plos One. 2012;7(6):e39075.
135. Dunkle LM, Izikson R. Recombinant hemagglutinin influenza vaccine provides broader spectrum protection. Expert Rev Vaccines. 2016;15(8):957–966.
136. Berlanda Scorza F, Tsvetnitsky V, Donnelly JJ. Universal influenza vaccines:shifting to better vaccines. Vaccine. 2016;34(26):2926–2933.• Excellent review summarizing universal/broadly protective influenza virus vaccine candidates in late preclinical and in clinical development.